Goat polyclonal antibody to human igg

Manufactured by Abcam

Sourced in United Kingdom

Goat polyclonal antibody to human IgG. This product is a purified immunoglobulin fraction from goat serum, which has been raised against human IgG.

Automatically generated - may contain errors

Lab products found in correlation

Stop solution, by Thermo Fisher Scientific (3 mentions) Carbonate coating buffer, by Thermo Fisher Scientific (2 mentions) Mage a4, by OriGene (2 mentions) Ca125, by R&D Systems (1 mentions) 3 3 5 5 tetramethylbenzidine (tmb), by Thermo Fisher Scientific (1 mentions) Tmb substrate, by Thermo Fisher Scientific (1 mentions) Tetramethylbenzidine substrate, by Thermo Fisher Scientific (1 mentions)

3 protocols using goat polyclonal antibody to human igg

Multiplex Serum Autoantibody Detection

Check if the same lab product or an alternative is used in the 5 most similar protocols

Recombinant proteins NY-ESO-1, Her-2/neu, MAGE-A4 (Origene, Rockville, US), CA125 (R&D Systems) and MAGE-A3, MAGE-A10 (Abnova, Taipei, Taiwan) were diluted in Carbonate Coating Buffer (Invitrogen, Prague, Czech Republic) to a final concentration of 1 μg/ml and coated to 96-well plates overnight at 4°C. Plates were blocked for 1 hour with Assay Buffer (Invitrogen, Carlsbad, CA). Patients and control sera diluted to 1:50, 1:100 and 1:200 were incubated in the antigen-coated wells for 2 h. Plates were then incubated with secondary antibody (goat polyclonal antibody to human IgG, Abcam, Cambridge, UK) for 1 hour. TMB (Invitrogen) was used as a substrate. Reaction was stopped after 20 minutes by adding Stop Solution (Invitrogen). Plates were immediately read with absorbance at 450 nm. As a positive control the Cytomegalovirus Glycoprotein B protein was used. The cutoff value designating positive reaction was assessed as the mean OD of 15 sera obtained from healthy controls (NHS) + 3SD.

Kloudová K., Hromádková H., Partlová S., Brtnický T., Rob L., Bartůňková J., Hensler M., Halaška M.J., Špíšek R, & Fialová A. (2016). Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines. Oncotarget, 7(29), 46120-46126.

+ Open protocol

+ Expand

ELISA for Detecting Anti-PSA and Anti-MAGE-3 Antibodies

Check if the same lab product or an alternative is used in the 5 most similar protocols

The recombinant proteins PSA and MAGE-3 (Abnova, Taipei, Taiwan) were diluted in Carbonate Coating Buffer (Life Technologies) to a final concentration of 1 μg/ml and were adhered to 96-well plates overnight at 4°C. The plates were blocked for 1 hour with Assay Buffer (Life Technologies), and then human sera diluted to 1:50, 1:100 and 1:200 were incubated in the antigen-coated wells for 2 h. The plates were then incubated with secondary antibody (goat polyclonal antibody to human IgG; Abcam, Cambridge, UK) for 1 hour. TMB substrate (Life Technologies) was then added and incubated for 20 minutes. The reaction was stopped by adding Stop Solution (Invitrogen, Prague, Czech Republic), and the plates were immediately read at an absorbance of 450 nm. As a positive control, cytomegalovirus glycoprotein B was used. The cutoff value designating a positive reaction was assessed as the mean OD of 15 healthy control human sera (NHS) + 3SD.

Podrazil M., Horvath R., Becht E., Rozkova D., Bilkova P., Sochorova K., Hromadkova H., Kayserova J., Vavrova K., Lastovicka J., Vrabcova P., Kubackova K., Gasova Z., Jarolim L., Babjuk M., Spisek R., Bartunkova J, & Fucikova J. (2015). Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget, 6(20), 18192-18205.

+ Open protocol

+ Expand

Detecting Tumor Antigens in NSCLC Serum

Check if the same lab product or an alternative is used in the 5 most similar protocols

The presence of antibodies against the three tumor antigens HER2/neu, NY-ESO-1, and MAGE-A4 in serum of patients with NSCLC and controls was detected by ELISA as adopted from Gnjatic et al., 13 Long et al., 14 and Stockert et al. 15 The recombinant proteins NY-ESO-1, HER-2/neu, and MAGE-A4 (Origene) were diluted in carbonate coating buffer (Invitrogen, Carlsbad, CA) to a final concentration of 1 mg/mL and coated to 96-well plates overnight at 4 C. Plates were blocked for 1 hour with Assay Buffer (Invitrogen). Human sera diluted to 1:100 and 1:200 were incubated in the antigen-coated wells for 2 hours. Plates were then incubated with secondary antibody (goat polyclonal antibody to human IgG [Abcam, Cambridge, United Kingdom]) for 1 hour. Tetramethylbenzidine substrate (Invitrogen) was added and incubated for 20 minutes. The reaction was stopped by adding Stop Solution (Invitrogen). Plates were immediately read with absorbance at 450 nm. As a positive control, the cytomegalovirus glycoprotein B protein was used.

Myšíková D., Adkins I., Hradilová N., Palata O., Šimonek J., Pozniak J., Kolařík J., Skallová-Fialová A., Špíšek R, & Lischke R. (2017). Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 12(2).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!